Vera Therapeutics, Inc.
VERA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | 1.57 | 0.00 | -0.35 |
| FCF Yield | -3.66% | -3.57% | -1.72% | -2.55% |
| EV / EBITDA | -20.67 | -26.73 | -55.03 | -54.94 |
| Quality | ||||
| ROIC | -14.68% | -9.70% | -7.74% | -14.48% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.72 | 1.05 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -0.76% | -37.08% | 35.76% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.38 | 0.01 | 0.92 | -0.62 |
| Interest Coverage | -42.76 | -31.92 | -26.14 | -25.72 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,103.25 | 0.00 | 0.00 | 0.00 |